Does weight change how well Cosentyx works in obese patients?
Cosentyx (secukinumab) is dosed by body weight-independent dosing (fixed dosing schedules rather than weight-based dosing). In clinical studies, efficacy and safety results were not shown to meaningfully differ by baseline body weight categories, including obese patients. [1]
What do the clinical data say for obese or higher body weight groups?
Across phase 3 psoriasis trials, analyses by baseline body weight did not show reduced effectiveness of secukinumab in participants with higher body weight/obesity compared with lower-weight groups. [1]
Is the dosing adjusted for body weight in Cosentyx?
No. Cosentyx is not adjusted based on patient weight; it uses fixed dosing regimens. [1]
What to know if you’re concerned about response in obesity
Because the drug is fixed-dose and weight-related differences were not observed in trial subgroup analyses, obesity alone has not been shown to require a Cosentyx dose change for efficacy. If response is inadequate, clinicians typically assess other factors that can affect treatment outcomes (such as adherence, disease severity, comorbidities, or whether the regimen and timing follow the recommended schedule). [1]
Sources
[1] Novartis. “COSENTYX (secukinumab) Prescribing Information.” (Body weight and obesity subgroup analyses; dosing is not weight-based.) https://www.accessdata.fda.gov/scripts/cder/daf/